Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles E de Bock

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Hemasphere|April 3, 2024
A new mouse model highlights the need for better JAK inhibitors in myeloproliferative neoplasmsCharles E de Bock
Hemasphere|April 17, 2025
Patient-derived xenografts: Practical considerations for preclinical drug testingCharles E de Bock
Hemasphere|October 14, 2024
Overcoming a T-ALL order: A comprehensive study linking genomics to clinical outcomesYizhou Huang, Charles E de Bock
Molecular & Cellular Oncology|September 26, 2018
JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemiaCharles E de Bock, Jan Cools
Hemasphere|November 24, 2025
A new KAT on the block rewrites the epigenetic script in menin inhibitor-resistant leukemiaYizhou Huang, Charles E de Bock
Hemasphere|January 24, 2025
Mastering fate: Redistributing a pioneer protein to rewrite leukemia's scriptYizhou Huang, Charles E de Bock
Nature Cancer|May 30, 2024
Selective targeting of malignant T cellsCharles E de Bock, Jan Cools
Cancer Cell|June 10, 2015
T-ALL: Home Is where the CXCL12 IsCharles E de Bock, Jan Cools
Blood|November 11, 2021
BETter insight into PRC2-mutated T-ALLCharles E de Bock, Jan Cools
Hemasphere|July 22, 2024
Less is more: Depleting myeloid-biased HSCs to restore immune functionHansen J Kosasih, Charles E de Bock
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Hemasphere|April 3, 2024
A new mouse model highlights the need for better JAK inhibitors in myeloproliferative neoplasmsCharles E de Bock
Hemasphere|April 17, 2025
Patient-derived xenografts: Practical considerations for preclinical drug testingCharles E de Bock
Hemasphere|October 14, 2024
Overcoming a T-ALL order: A comprehensive study linking genomics to clinical outcomesYizhou Huang, Charles E de Bock
Molecular & Cellular Oncology|September 26, 2018
JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemiaCharles E de Bock, Jan Cools
Hemasphere|November 24, 2025
A new KAT on the block rewrites the epigenetic script in menin inhibitor-resistant leukemiaYizhou Huang, Charles E de Bock
Hemasphere|January 24, 2025
Mastering fate: Redistributing a pioneer protein to rewrite leukemia's scriptYizhou Huang, Charles E de Bock
Nature Cancer|May 30, 2024
Selective targeting of malignant T cellsCharles E de Bock, Jan Cools
Cancer Cell|June 10, 2015
T-ALL: Home Is where the CXCL12 IsCharles E de Bock, Jan Cools
Blood|November 11, 2021
BETter insight into PRC2-mutated T-ALLCharles E de Bock, Jan Cools
Hemasphere|July 22, 2024
Less is more: Depleting myeloid-biased HSCs to restore immune functionHansen J Kosasih, Charles E de Bock
Pageof 7